https://www.pharmaradar360.com/article/moderna-vaccinates-first-participants-in-trial-for-ebola-strain-with-no-vaccine-099d86bafa7f5d57Pharma Surgeen2026-08-04T15:00:00.000ZModerna vaccinates first participants in trial for Ebola strain with no vaccinehttps://www.pharmaradar360.com/article/decision-suspended-and-revoked-licences-and-registrations-for-manufacturers-and-78d9f009f9f0c1ecPharma Surgeen2026-08-04T14:45:10.000ZDecision: Suspended and revoked licences and registrations for manufacturers and wholesalers of medicines and ingredientshttps://www.pharmaradar360.com/article/best-practice-for-prescribing-drugs-with-dependence-potential-a90bf0d3232249d7Pharma Surgeen2026-08-04T14:41:55.000ZBest practice for prescribing drugs with dependence potentialhttps://www.pharmaradar360.com/article/field-safety-notices-27-to-31-july-2026-14c7d35058125725Pharma Surgeen2026-08-04T14:34:58.000ZField Safety Notices: 27 to 31 July 2026https://www.pharmaradar360.com/article/gammagard-liquid-erc-approved-for-primary-immunodeficiency-52762ed5f81e20c3Pharma Surgeen2026-08-04T14:26:15.000ZGAMMAGARD LIQUID ERC Approved for Primary Immunodeficiencyhttps://www.pharmaradar360.com/article/fda-accepts-takeda-s-entyvio-bla-1b63e4e8e35735baPharma Surgeen2026-08-04T14:26:15.000ZFDA Accepts Takeda’s Entyvio BLAhttps://www.pharmaradar360.com/article/medicines-for-europe-calls-for-biotech-act-reforms-to-address-biosimilar-void-d61ea82629e90ab7Pharma Surgeen2026-08-04T14:20:35.000ZMedicines for Europe calls for Biotech Act reforms to address ‘biosimilar void’https://www.pharmaradar360.com/article/once-weekly-hiv-therapy-may-offer-alternative-to-daily-pills-a43dc2511ee1d037Pharma Surgeen2026-08-04T14:11:36.000ZOnce-weekly HIV therapy may offer alternative to daily pillshttps://www.pharmaradar360.com/article/can-data-prevent-the-next-drug-shortage-02a46b1dba9a75b6Pharma Surgeen2026-08-04T14:01:53.000ZCan Data Prevent the Next Drug Shortage?https://www.pharmaradar360.com/article/fiercest-women-in-life-sciences-2026-nominations-open-now-5a8ba991aa030142Pharma Surgeen2026-08-04T14:00:00.000ZFiercest Women in Life Sciences 2026: Nominations open nowhttps://www.pharmaradar360.com/article/q-a-scoring-drug-supply-chains-for-resilience-not-just-price-9b29bbd55273976cPharma Surgeen2026-08-04T13:51:53.000ZQ&A: Scoring Drug Supply Chains for Resilience, Not Just Pricehttps://www.pharmaradar360.com/article/liebel-flarsheim-company-llc-issues-recall-of-optiray-imaging-bulk-package-350-5-3d8846a05411a510Pharma Surgeen2026-08-04T13:50:32.000ZLiebel-Flarsheim Company, LLC Issues Recall of OPTIRAY Imaging Bulk Package - 350, 500mL, Vial, Nationwide and Mexico Due to Presence of Particulate Matterhttps://www.pharmaradar360.com/article/holland-knight-health-dose-august-4-2026-f32f915714d7579aPharma Surgeen2026-08-04T13:41:10.000ZHolland & Knight Health Dose: August 4, 2026https://www.pharmaradar360.com/article/biopharmaceutical-pat-market-forecast-to-reach-4-32bn-a1ad365ea06beadcPharma Surgeen2026-08-04T13:38:58.000ZBiopharmaceutical PAT market forecast to reach $4.32bnhttps://www.pharmaradar360.com/article/industry-and-patient-groups-divided-over-eu-biotech-plans-7d8a11a041273600Pharma Surgeen2026-08-04T13:24:37.000ZIndustry and patient groups divided over EU biotech planshttps://www.pharmaradar360.com/article/new-green-hemp-inc-otc-nghi-announces-strategic-vision-following-ecogreen-biotec-83967c236ecf6566Pharma Surgeen2026-08-04T13:23:18.000ZNew Green Hemp, Inc. (OTC: NGHI) Announces Strategic Vision Following EcoGreen Biotech Acquisitionhttps://www.pharmaradar360.com/article/opus-genetics-completes-enrollment-in-phase-3-trial-of-gene-therapy-for-inherite-d0ab02b1ab5f96f3Pharma Surgeen2026-08-04T13:06:40.000ZOpus Genetics Completes Enrollment in Phase 3 Trial of Gene Therapy for Inherited Retinal Diseasehttps://www.pharmaradar360.com/article/four-strategies-for-winning-not-just-reaching-the-biotech-launch-stage-7ddbf8f3c9e8055bPharma Surgeen2026-08-04T13:04:11.000ZFour strategies for winning, not just reaching, the biotech launch stagehttps://www.pharmaradar360.com/article/cordis-project-developing-broad-spectrum-antiviral-drugs-for-pandemic-preparedne-57d9451498d15c35Pharma Surgeen2026-08-04T13:00:37.000ZCORDIS project: Developing broad-spectrum antiviral drugs for pandemic preparednesshttps://www.pharmaradar360.com/article/cordis-project-next-generation-tools-for-genome-centric-multimodal-data-integrat-65f98babc258c91fPharma Surgeen2026-08-04T13:00:14.000ZCORDIS project: NEXT GENERATION TOOLS FOR GENOME-CENTRIC MULTIMODAL DATA INTEGRATION IN PERSONALISED CARDIOVASCULAR MEDICINEhttps://www.pharmaradar360.com/article/drager-atlan-anaesthesia-workstations-risk-of-ventilator-failure-dsi-2026-005-86d0209f38290fddPharma Surgeen2026-08-04T13:00:13.000ZDräger Atlan Anaesthesia workstations: risk of ventilator failure (DSI/2026/005)https://www.pharmaradar360.com/article/cordis-project-virtual-twins-as-tools-for-personalised-clinical-care-c6190e9b6108c511Pharma Surgeen2026-08-04T13:00:00.000ZCORDIS project: VIrtual Twins as tools for personalised clinicAL carehttps://www.pharmaradar360.com/article/cordis-project-european-action-for-the-diagnosis-of-early-non-clinical-type-1-di-49a2c916e6ec3ffbPharma Surgeen2026-08-04T12:59:45.000ZCORDIS project: European action for the Diagnosis of Early Non-clinical Type 1 diabetes For disease Interceptionhttps://www.pharmaradar360.com/article/chromatography-columns-market-to-reach-usd-4-22-billion-by-2031-e1d0e03a7db19b2dPharma Surgeen2026-08-04T12:54:38.000ZChromatography columns market to reach USD 4.22 billion by 2031https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-shenyang-xingqi-pharmaceutical-co-ltd-clas-56616decd672aacaPharma Surgeen2026-08-04T12:52:23.000ZEnterprise value to EBITDA forward of Shenyang Xingqi Pharmaceutical Co., Ltd. Class A – SZSE:300573https://www.pharmaradar360.com/article/amplia-signs-collaboration-agreement-with-lilly-evaluating-narmafotinib-plus-lil-e8c1c76d667728c8Pharma Surgeen2026-08-04T12:45:00.000ZAmplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancerhttps://www.pharmaradar360.com/article/amplia-s-two-drug-lung-cancer-trial-is-planned-for-late-2026-a26adf574ed6a74ePharma Surgeen2026-08-04T12:45:00.000ZAmplia's two-drug lung cancer trial is planned for late 2026https://www.pharmaradar360.com/article/cordis-project-next-generation-toolbox-for-greener-pharmaceuticals-design-manufa-54347cb6058aea6aPharma Surgeen2026-08-04T12:22:33.000ZCORDIS project: Next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impacthttps://www.pharmaradar360.com/article/is-cbd-gummies-considered-a-drug-view-wimdutmcg-f8e7311ffa67f821Pharma Surgeen2026-08-04T12:21:09.000ZIs CBD Gummies Considered a Drug - View WIMdutmcGhttps://www.pharmaradar360.com/article/fda-approves-long-lasting-otc-pain-reliever-combining-acetaminophen-and-naproxen-b705877d8a45bc85Pharma Surgeen2026-08-04T12:15:11.000ZFDA approves long-lasting OTC pain reliever combining acetaminophen and naproxenhttps://www.pharmaradar360.com/article/pharmd-students-explore-antioxidants-in-invasive-plants-and-root-tea-6d866f405ffef86bPharma Surgeen2026-08-04T12:08:15.000ZPharmD students explore antioxidants in invasive plants and root teahttps://www.pharmaradar360.com/article/cmps-stock-clocks-muted-gains-but-analysts-back-psychedelic-drug-s-durability-ah-6a4a3cae17e5d82cPharma Surgeen2026-08-04T12:01:55.000ZCMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filinghttps://www.pharmaradar360.com/article/needle-kit-for-powered-driver-f9c845aef89e5e4fPharma Surgeen2026-08-04T12:00:00.000ZNeedle Kit For Powered Driverhttps://www.pharmaradar360.com/article/allergan-aesthetics-announces-u-s-fda-acceptance-of-supplemental-biologics-licen-d7110669fee8b3b0Pharma Surgeen2026-08-04T12:00:00.000ZAllergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominencehttps://www.pharmaradar360.com/article/longevity-wellness-pharmaceutical-market-global-industry-analysis-and-opportunit-ad3b64a2e72f3cbePharma Surgeen2026-08-04T11:55:41.000ZLongevity Wellness Pharmaceutical Market : Global Industry Analysis and Opportunity Assessment, 2036https://www.pharmaradar360.com/article/latigo-laces-up-for-247m-ipo-to-fund-non-opioid-pain-drug-rival-to-vertex-s-jour-695bcced0b6a2918Pharma Surgeen2026-08-04T11:55:09.000ZLatigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavxhttps://www.pharmaradar360.com/article/astrazeneca-bristol-myers-brace-for-a-biotech-m-a-boom-8083a001612aaa91Pharma Surgeen2026-08-04T11:53:00.000ZAstraZeneca-Bristol Myers: Brace for a Biotech M&A Boomhttps://www.pharmaradar360.com/article/astrazeneca-s-bristol-myers-flirtation-exposes-the-bargain-between-britain-and-i-f6af0102079b20caPharma Surgeen2026-08-04T11:43:50.000ZAstraZeneca's Bristol Myers Flirtation Exposes the Bargain Between Britain and Its Pharmaceutical Championhttps://www.pharmaradar360.com/article/bayer-holds-guidance-as-pharma-sales-flatten-in-second-quarter-49c05be70b96b7cdPharma Surgeen2026-08-04T11:32:22.000ZBayer holds guidance as pharma sales flatten in second quarterhttps://www.pharmaradar360.com/article/merck-raises-sales-forecasts-c9fd28f082dff3dbPharma Surgeen2026-08-04T11:30:32.000ZMerck raises sales forecastshttps://www.pharmaradar360.com/article/how-a-scottish-biotech-company-is-turning-whisky-waste-into-a-sustainable-source-6cb137ba0c9915f2Pharma Surgeen2026-08-04T11:26:00.000ZHow a Scottish biotech company is turning whisky waste into a sustainable source of omega-3https://www.pharmaradar360.com/article/keep-britain-working-review-update-june-2026-bac12cbf358b7e62Pharma Surgeen2026-08-04T11:18:56.000ZKeep Britain Working review update: June 2026https://www.pharmaradar360.com/article/etfs-investing-in-shanghai-fosun-pharmaceutical-group-co-ltd-class-h-stocks-70e1c5e4f4ce7f05Pharma Surgeen2026-08-04T11:17:48.000ZETFs Investing in Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class H Stockshttps://www.pharmaradar360.com/article/access-expanding-for-experimental-weight-loss-drug-633171a578097d6ePharma Surgeen2026-08-04T11:16:00.000ZAccess expanding for experimental weight loss drughttps://www.pharmaradar360.com/article/pediatric-dermatology-s-blind-spot-how-arcutis-built-a-drug-pipeline-where-the-i-fe269df95966ee0ePharma Surgeen2026-08-04T11:03:36.000ZPediatric Dermatology’s Blind Spot: How Arcutis Built a Drug Pipeline Where the Industry Wouldn’t Lookhttps://www.pharmaradar360.com/article/tick-borne-encephalitis-the-green-book-a0d466d697080d92Pharma Surgeen2026-08-04T11:00:06.000ZTick-borne encephalitis: the green bookhttps://www.pharmaradar360.com/article/tiziana-life-sciences-announces-purchase-of-shares-by-chief-executive-officer-749670c1c346d359Pharma Surgeen2026-08-04T11:00:00.000ZTiziana Life Sciences Announces Purchase of Shares by Chief Executive Officerhttps://www.pharmaradar360.com/article/8-01d91eaf03e519f6Pharma Surgeen2026-08-04T11:00:00.000Z「令和8年熊本地震」による災害に対する義援金についてhttps://www.pharmaradar360.com/article/mfn-one-year-on-a-review-of-the-17-trumprx-deals-ccfc3723088cad6cPharma Surgeen2026-08-04T10:52:30.000ZMFN one year on: a review of the 17 TrumpRx dealshttps://www.pharmaradar360.com/article/eli-lilly-retatrutide-early-access-opens-to-a-small-group-of-patients-before-fda-4a8a0f6f236d225cPharma Surgeen2026-08-04T10:48:43.000ZEli Lilly Retatrutide Early Access Opens to a Small Group of Patients Before FDA Approvalhttps://www.pharmaradar360.com/article/tasrif-pharmaceutical-granted-second-us-patent-for-cd155-targeting-antibody-deve-b3114cc2ebf7608bPharma Surgeen2026-08-04T10:40:14.000ZTasrif Pharmaceutical granted second US patent for CD155-targeting antibody developed with Abzena's humanisation and immunogenicity platformshttps://www.pharmaradar360.com/article/enrolment-concludes-in-4moving-biotech-s-phase-iia-trial-of-4p004-4cb19237c85d87fcPharma Surgeen2026-08-04T10:36:02.000ZEnrolment concludes in 4Moving Biotech’s Phase IIa trial of 4P004https://www.pharmaradar360.com/article/merck-hikes-revenue-outlook-as-new-drug-sales-grow-but-cuts-profit-guidance-due-62a5117d666b6171Pharma Surgeen2026-08-04T10:34:21.000ZMerck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal chargeshttps://www.pharmaradar360.com/article/merck-038-co-inc-rahway-n-j-usa-announces-second-quarter-2026-financial-results-bf1813c57365d4a5Pharma Surgeen2026-08-04T10:30:00.000ZMerck &#038; Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipelinehttps://www.pharmaradar360.com/article/business-brief-canadian-biotech-sector-finds-fresh-backing-from-foreign-investor-778efafda57a89b0Pharma Surgeen2026-08-04T10:15:28.000ZBusiness Brief: Canadian biotech sector finds fresh backing – from foreign investorshttps://www.pharmaradar360.com/article/teva-teva-is-up-8-8-after-raising-2026-guidance-and-highlighting-innovative-drug-ca4f8be5844b4432Pharma Surgeen2026-08-04T10:09:44.000ZTeva (TEVA) Is Up 8.8% After Raising 2026 Guidance And Highlighting Innovative Drug Momentumhttps://www.pharmaradar360.com/article/what-to-know-about-the-new-wave-of-biotech-beauty-0686b992c03a8b71Pharma Surgeen2026-08-04T10:05:25.000ZWhat to Know About the New Wave of Biotech Beautyhttps://www.pharmaradar360.com/article/addressing-china-s-rise-in-biotech-by-removing-barriers-q-a-with-john-stanford-338ef1cadbf57c0cPharma Surgeen2026-08-04T10:03:21.000ZAddressing China’s Rise in Biotech by Removing Barriers: Q&A with John Stanfordhttps://www.pharmaradar360.com/article/seventh-meeting-of-the-subsidiary-body-on-implementation-sbi-7-digital-sequence-0a8debc65bf10547Pharma Surgeen2026-08-04T10:00:04.000ZSeventh meeting of the Subsidiary Body on Implementation (SBI-7): Digital sequence information on genetic resourceshttps://www.pharmaradar360.com/article/danske-bank-sees-zealand-pharma-as-potential-big-pharma-takeover-target-8a8bf26f03e07c8cPharma Surgeen2026-08-04T09:59:30.000ZDanske Bank sees Zealand Pharma as potential "big pharma" takeover targethttps://www.pharmaradar360.com/article/the-manufacturers-life-insurance-company-sells-155-079-shares-of-teva-pharmaceut-f601380919fef454Pharma Surgeen2026-08-04T09:57:35.000ZThe Manufacturers Life Insurance Company Sells 155,079 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/samsung-pharmaceutical-co-ltd-revenue-breakdown-krx-001360-2e3253c651533924Pharma Surgeen2026-08-04T09:55:48.000ZSAMSUNG PHARMACEUTICAL.CO.,Ltd. Revenue Breakdown – KRX:001360https://www.pharmaradar360.com/article/cbd-gummies-safety-fda-warnings-2025-2026-view-ljrkshymf-7fa8c84ea088fdc8Pharma Surgeen2026-08-04T09:33:32.000Zcbd gummies safety fda warnings 2025 2026 - View ljRKshymFhttps://www.pharmaradar360.com/article/biotech-investors-are-waiting-for-the-wrong-milestone-in-ai-drug-discovery-ec4750778ceb31e6Pharma Surgeen2026-08-04T09:24:00.000ZBiotech Investors Are Waiting For The Wrong Milestone In AI Drug Discoveryhttps://www.pharmaradar360.com/article/icymi-fda-clears-medicus-to-begin-gorlin-syndrome-skinject-trial-6f62f0743b8873c0Pharma Surgeen2026-08-04T09:22:30.000ZICYMI: FDA Clears Medicus to Begin Gorlin Syndrome SkinJect Trialhttps://www.pharmaradar360.com/article/is-cbd-gummies-considered-drugs-view-p3la5tmpg-b9ab8bf80b8cb29fPharma Surgeen2026-08-04T09:12:20.000ZIs CBD Gummies Considered Drugs - View p3La5TMPGhttps://www.pharmaradar360.com/article/digital-health-firm-launches-integrated-glp-1-program-810e6ed260dbebdcPharma Surgeen2026-08-04T09:11:30.000ZDigital Health Firm Launches Integrated GLP-1 Programhttps://www.pharmaradar360.com/article/where-ai-fits-in-the-future-of-drug-development-22862ec014b32c3fPharma Surgeen2026-08-04T09:10:40.000ZWhere AI Fits in the Future of Drug Developmenthttps://www.pharmaradar360.com/article/does-making-cbd-gummier-to-sell-require-fda-approval-view-jkogsldni-df9d15278b902f58Pharma Surgeen2026-08-04T09:09:41.000Zdoes making cbd gummier to sell require fda approval - View jKogsldNihttps://www.pharmaradar360.com/article/has-canada-s-biotech-moment-finally-arrived-3f24645bbf3c109fPharma Surgeen2026-08-04T09:00:00.000ZHas Canada’s biotech moment finally arrived?https://www.pharmaradar360.com/article/amgen-contends-with-data-breach-exposing-patient-information-d6db659defb2d7c3Pharma Surgeen2026-08-04T08:57:27.000ZAmgen contends with data breach, exposing patient informationhttps://www.pharmaradar360.com/article/astrazeneca-shares-slump-after-400bn-bms-merger-rumours-71cf1f553cc60264Pharma Surgeen2026-08-04T08:57:27.000ZAstraZeneca shares slump after $400bn BMS merger rumourshttps://www.pharmaradar360.com/article/cbd-gummies-safety-who-should-avoid-them-according-to-fda-stance-view-bzizhv2ya-5af4f39494df27c4Pharma Surgeen2026-08-04T08:49:30.000ZCBD Gummies Safety: Who Should Avoid Them According to FDA Stance - View bzizhV2yahttps://www.pharmaradar360.com/article/wuxi-apptec-s-support-for-small-and-emerging-biotech-companies-three-global-exam-bdc2d5e77b5146a0Pharma Surgeen2026-08-04T08:45:00.000ZWuXi AppTec' s Support for Small and Emerging Biotech Companies: Three Global Exampleshttps://www.pharmaradar360.com/article/fda-peptide-vote-explained-why-these-drugs-are-not-approved-yet-2317de365de96d54Pharma Surgeen2026-08-04T08:32:27.000ZFDA peptide vote explained: Why these drugs are not approved yethttps://www.pharmaradar360.com/article/krystal-biotech-inc-at-td-cowen-healthcare-conference-transcript-e9dcc23e9e9298bfPharma Surgeen2026-08-04T08:31:13.000ZKrystal Biotech Inc at TD Cowen Healthcare Conference Transcripthttps://www.pharmaradar360.com/article/real-world-safety-profile-of-fezolinetant-a-disproportionality-analysis-based-on-f61d94977f148936Pharma Surgeen2026-08-04T08:30:24.000ZReal-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS databasehttps://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-ango-anik-elox-yarw-plse-5c90b1e31c120a35Pharma Surgeen2026-08-04T08:17:00.000ZBiotech Stocks At 52-Week Highs - ANGO, ANIK, ELOX, YARW, PLSEhttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-sa-declaration-relative-to-the-number-of-shares-and-vot-42080c56f7a29d92Pharma Surgeen2026-08-04T08:11:37.000ZSartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITALhttps://www.pharmaradar360.com/article/pharmaceutical-care-group-affordability-for-prescription-drugs-requires-examinat-3bb6956da548b955Pharma Surgeen2026-08-04T08:00:00.000ZPharmaceutical care group: Affordability for prescription drugs requires examination of the entire supply chainhttps://www.pharmaradar360.com/article/biotech-cbd-gummies-a-balanced-look-at-gummies-with-cannabidiol-view-lzhhilm6m-c907dc0bbd403a2bPharma Surgeen2026-08-04T07:57:21.000ZBiotech CBD Gummies: A Balanced Look at Gummies with Cannabidiol - View LzhhILM6mhttps://www.pharmaradar360.com/article/eli-lilly-to-offer-limited-early-access-to-experimental-weight-loss-drug-1212a3f754be31f4Pharma Surgeen2026-08-04T07:48:00.000ZEli Lilly to offer limited early access to experimental weight-loss drughttps://www.pharmaradar360.com/article/opus-genetics-completes-enrollment-in-opgx-lca5-phase-3-trial-cbeeec92db860353Pharma Surgeen2026-08-04T07:38:27.000ZOpus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trialhttps://www.pharmaradar360.com/article/amsilk-collaboration-biotech-silk-protein-yarns-feature-in-balenciaga-55th-coutu-4cee326b299f9142Pharma Surgeen2026-08-04T07:30:00.000ZAMSilk collaboration: Biotech silk protein yarns feature in Balenciaga 55th Couture Collectionhttps://www.pharmaradar360.com/article/potential-astrazeneca-bristol-myers-mega-merger-could-trigger-new-m-a-wave-baaa266ed97d1746Pharma Surgeen2026-08-04T07:20:38.000ZPotential AstraZeneca-Bristol Myers mega-merger could trigger new M&A wavehttps://www.pharmaradar360.com/article/stephanie-lueras-why-do-pharmaceutical-commercials-have-such-long-warning-lists-feede09ed38e1b21Pharma Surgeen2026-08-04T07:15:00.000ZStephanie Lueras: Why do pharmaceutical commercials have such long warning lists?https://www.pharmaradar360.com/article/price-to-sales-forward-of-shenyang-xingqi-pharmaceutical-co-ltd-class-a-szse-300-eaaf695635d81c9dPharma Surgeen2026-08-04T07:05:20.000ZPrice to sales forward of Shenyang Xingqi Pharmaceutical Co., Ltd. Class A – SZSE:300573https://www.pharmaradar360.com/article/la-aemps-informa-sobre-el-uso-correcto-de-los-desinfectantes-de-piel-sana-63f180a51e53e52bPharma Surgeen2026-08-04T07:00:51.000ZLa AEMPS informa sobre el uso correcto de los desinfectantes de piel sanahttps://www.pharmaradar360.com/article/former-novo-nordisk-north-america-chief-joins-board-of-us-biotech-company-65e268eb70e03273Pharma Surgeen2026-08-04T06:55:45.000ZFormer Novo Nordisk North America chief joins board of US biotech companyhttps://www.pharmaradar360.com/article/clinical-trials-sellas-life-sciences-09006b8e86504c0bPharma Surgeen2026-08-04T06:43:57.000ZClinical Trials - Sellas Life Scienceshttps://www.pharmaradar360.com/article/nurix-starts-phase-3-trial-of-bexobrutideg-against-pirtobrutinib-in-cll-ee7981e5aeaf0b96Pharma Surgeen2026-08-04T06:33:26.000ZNurix Starts Phase 3 Trial of Bexobrutideg Against Pirtobrutinib in CLLhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-ch-biotech-r-d-co-ltd-twse-6534-517b6aad6cc9abb4Pharma Surgeen2026-08-04T06:29:45.000ZPrice to earnings forward of CH Biotech R&D Co., Ltd. – TWSE:6534https://www.pharmaradar360.com/article/which-hotels-follow-fssai-rules-maharashtra-fda-has-no-official-list-71971379ebdc02d4Pharma Surgeen2026-08-04T06:26:00.000ZWhich hotels follow FSSAI rules? Maharashtra FDA has no official listhttps://www.pharmaradar360.com/article/announcement-of-partnership-with-the-japan-basketball-association-jba-65999e5dbe1c620aPharma Surgeen2026-08-04T06:01:34.000ZAnnouncement of Partnership with the Japan Basketball Association (JBA)https://www.pharmaradar360.com/article/sumitomo-pharma-contributes-to-relief-efforts-for-the-2026-kumamoto-earthquake-b097ac38bebdfe05Pharma Surgeen2026-08-04T06:00:00.000ZSumitomo Pharma Contributes to Relief Efforts for the 2026 Kumamoto Earthquakehttps://www.pharmaradar360.com/article/25-transfers-in-20-years-who-is-ias-tukaram-mundhe-why-his-fda-crackdown-reached-bc1e9433e391b491Pharma Surgeen2026-08-04T05:57:59.000Z25 Transfers in 20 Years: Who is IAS Tukaram Mundhe, why his FDA crackdown reached Bombay High Court?https://www.pharmaradar360.com/article/pharmaceutical-giants-astrazeneca-and-bristol-myers-squibb-are-in-merger-talks-c-0009f1e915d58d59Pharma Surgeen2026-08-04T05:50:57.000ZPharmaceutical giants AstraZeneca and Bristol-Myers Squibb are in merger talks; combined market value could exceed 2.7 trillion yuan - ChemNethttps://www.pharmaradar360.com/article/india-pharma-sector-to-miss-2030-sales-target-amid-tariff-and-shipping-woes-trad-556010eeca1bbe5dPharma Surgeen2026-08-04T05:34:01.000ZIndia pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body sayshttps://www.pharmaradar360.com/article/beyond-the-law-fda-oversight-and-grow-consumer-upgrade-skills-safety-f8d1a397e594bed7Pharma Surgeen2026-08-04T05:33:21.000ZBeyond the Law: FDA Oversight and Grow Consumer Upgrade-skills Safetyhttps://www.pharmaradar360.com/article/more-biotech-m-a-is-coming-whether-an-astrazeneca-bristol-myers-deal-happens-or-a6bd6670e70b54a0Pharma Surgeen2026-08-04T05:30:00.000ZMore Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Nothttps://www.pharmaradar360.com/article/price-to-book-forward-of-ch-biotech-r-d-co-ltd-twse-6534-e217e7bd4dbef02fPharma Surgeen2026-08-04T05:28:22.000ZPrice to book forward of CH Biotech R&D Co., Ltd. – TWSE:6534https://www.pharmaradar360.com/article/nurix-enrolls-first-patient-in-phase-3-trial-for-cll-drug-6da672a3d1c1d534Pharma Surgeen2026-08-04T05:12:46.000ZNurix enrolls first patient in phase 3 trial for CLL drughttps://www.pharmaradar360.com/article/nurix-therapeutics-announces-first-patient-enrolled-in-phase-3-daybreak-cll-306-be464a98cd5566dcPharma Surgeen2026-08-04T05:10:00.000ZNurix Therapeutics Announces First Patient Enrolled in Phase 3 DAYBreak CLL-306 Study of Bexobrutideg in Relapsed/Refractory CLL/SLLhttps://www.pharmaradar360.com/article/nurix-phase-3-trial-tests-bexobrutideg-against-cll-standard-of-care-07cd08068222451bPharma Surgeen2026-08-04T05:03:02.000ZNurix Phase 3 Trial Tests Bexobrutideg Against CLL Standard of Carehttps://www.pharmaradar360.com/article/4moving-biotech-completes-enrollment-in-phase-2a-inflam-motion-study-evaluating-4bd7377c4dab05f8Pharma Surgeen2026-08-04T05:01:08.000Z4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritishttps://www.pharmaradar360.com/article/4moving-biotech-dced3c53d13d0edfPharma Surgeen2026-08-04T05:01:08.000Z4MOVING-BIOTECHhttps://www.pharmaradar360.com/article/regarding-a-report-concerning-sumitomo-pharma-55498f8790dbeb7cPharma Surgeen2026-08-04T05:00:00.000ZRegarding a Report Concerning Sumitomo Pharmahttps://www.pharmaradar360.com/article/4moving-biotech-completes-enrollment-in-phase-2a-inflam-motion-study-evaluating-066f8a631fc2cf1fPharma Surgeen2026-08-04T05:00:00.000Z4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritishttps://www.pharmaradar360.com/article/have-you-heard-of-biotech-beauty-we-took-a-closer-look-273b6fccdba886b5Pharma Surgeen2026-08-04T04:39:43.000ZHave you heard of biotech beauty? We took a closer lookhttps://www.pharmaradar360.com/article/does-tukaram-mundhe-receive-threats-after-action-against-restaurants-maharashtra-91715512912c9eacPharma Surgeen2026-08-04T04:38:02.000ZDoes Tukaram Mundhe Receive Threats After Action Against Restaurants? Maharashtra FDA Chief Respondshttps://www.pharmaradar360.com/article/peptides-find-their-way-to-the-public-a38a5de7d0976a3dPharma Surgeen2026-08-04T04:05:00.000ZPeptides Find Their Way to the Publichttps://www.pharmaradar360.com/article/krystal-biotech-inc-unsponsored-bdr-revenue-breakdown-bmfbovespa-k1ys34-a75951c9b1bbc213Pharma Surgeen2026-08-04T03:39:04.000ZKrystal Biotech Inc Unsponsored BDR Revenue Breakdown – BMFBOVESPA:K1YS34https://www.pharmaradar360.com/article/ever-supreme-bio-s-july-revenue-hits-nt-99-25-million-a-2025-high-cell-therapy-d-ea583d4cedad45f5Pharma Surgeen2026-08-04T03:16:00.000ZEver Supreme Bio's July Revenue Hits NT$99.25 Million, a 2025 High; Cell Therapy Drug Advances to Phase 2a Clinical Trialhttps://www.pharmaradar360.com/article/amplia-therapeutics-partners-with-lilly-on-lung-cancer-combination-trial-859357a78be1196bPharma Surgeen2026-08-04T03:12:34.000ZAmplia Therapeutics partners with Lilly on lung cancer combination trialhttps://www.pharmaradar360.com/article/neurizon-advances-als-trial-in-q4-fy26-179787d24b64ff0cPharma Surgeen2026-08-04T03:12:00.000ZNeurizon advances ALS trial in Q4 FY26https://www.pharmaradar360.com/article/cytiva-partners-with-mycenax-biotech-to-build-ai-driven-and-future-ready-downstr-1e570b454b1e83efPharma Surgeen2026-08-04T03:01:33.000ZCytiva Partners with Mycenax Biotech to Build AI-Driven and Future-Ready Downstream Bioprocessinghttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-avarept-67d65f5d4ba4aa36Pharma Surgeen2026-08-04T03:00:00.000Z[SHINSA]English Translation of Review Report: Avarepthttps://www.pharmaradar360.com/article/krystal-biotech-inc-krys-q2-2026-earnings-call-highlights-v-1edf1c4533ca7860Pharma Surgeen2026-08-04T03:00:00.000ZKrystal Biotech Inc (KRYS) (Q2 2026) Earnings Call Highlights: Vhttps://www.pharmaradar360.com/article/sumitomo-pharma-s-enzomenib-gets-orphan-drug-designation-by-us-fda-c915c5e89ad58581Pharma Surgeen2026-08-04T02:46:21.000ZSumitomo Pharma's Enzomenib gets Orphan Drug Designation by US FDAhttps://www.pharmaradar360.com/article/stoke-therapeutics-announces-second-quarter-2026-financial-results-and-provides-548819893736a12dPharma Surgeen2026-08-04T02:30:55.000ZStoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updateshttps://www.pharmaradar360.com/article/amplia-teams-up-with-big-pharma-for-lung-cancer-trial-22c49f021e63d5baPharma Surgeen2026-08-04T02:23:45.000ZAmplia teams up with big pharma for lung cancer trialhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-zhejiang-tianyu-pharmaceutical-co-ltd-class-69fe1c13ba03471fPharma Surgeen2026-08-04T02:20:05.000ZEnterprise value to EBIT forward of Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A – SZSE:300702https://www.pharmaradar360.com/article/otsuka-unveils-unprecedented-phase-3-visionary-two-year-egfr-results-demonstrati-34692e78f06f183bPharma Surgeen2026-08-04T02:04:45.000ZOtsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathyhttps://www.pharmaradar360.com/article/maharashtra-fda-has-no-list-of-fssai-compliant-restaurants-despite-crackdown-6c6e5261fabe6a93Pharma Surgeen2026-08-04T02:01:00.000ZMaharashtra FDA has no list of FSSAI-compliant restaurants despite crackdownhttps://www.pharmaradar360.com/article/otsuka-sponsors-the-20th-asian-games-aichi-nagoya-2026-supporting-conditioning-a-ec4f1cfe8b4b60dePharma Surgeen2026-08-04T02:00:00.000ZOtsuka Sponsors the 20th Asian Games Aichi-Nagoya 2026 Supporting Conditioning and Performance with the Global Brand POCARI SWEAThttps://www.pharmaradar360.com/article/krystal-biotech-krys-stock-price-drops-as-premium-expectations-reset-a509dbcb81fac63aPharma Surgeen2026-08-04T01:01:51.000ZKrystal Biotech (KRYS) Stock Price Drops As Premium Expectations Resethttps://www.pharmaradar360.com/article/amplia-therapeutics-partners-with-eli-lilly-in-fak-kras-combination-lung-cancer-e200f7f2de36753aPharma Surgeen2026-08-04T00:44:05.000ZAmplia Therapeutics Partners with Eli Lilly in FAK-KRAS Combination Lung Cancer Trialhttps://www.pharmaradar360.com/article/chop-linked-drug-candidate-acquired-by-iceland-biotech-53bbd1d1ea1c0753Pharma Surgeen2026-08-04T00:27:00.000ZCHOP-linked drug candidate acquired by Iceland biotechhttps://www.pharmaradar360.com/article/fargo-sets-october-special-election-on-ward-system-approves-15m-biotech-tax-ince-d6d8d9175e8ad9daPharma Surgeen2026-08-04T00:13:44.000ZFargo sets October special election on ward system, approves $15M biotech tax incentivehttps://www.pharmaradar360.com/article/the-fda-must-reinstate-safety-restrictions-for-abortion-drug-6c871155713a602cPharma Surgeen2026-08-04T00:01:53.000ZThe FDA Must Reinstate Safety Restrictions for Abortion Drughttps://www.pharmaradar360.com/article/pfizer-filed-form-10-q-7034e6fb9b5a4852Pharma Surgeen2026-08-04T00:00:00.000ZPfizer filed Form 10-Qhttps://www.pharmaradar360.com/article/pfizer-filed-form-8-k-f63d17532d833857Pharma Surgeen2026-08-04T00:00:00.000ZPfizer filed Form 8-Khttps://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-45286f97031e8f83Pharma Surgeen2026-08-04T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/merck-filed-form-8-k-90aede6fe1e857e3Pharma Surgeen2026-08-04T00:00:00.000ZMerck filed Form 8-Khttps://www.pharmaradar360.com/article/johnson-johnson-filed-form-8-k-653fe6338bab75b5Pharma Surgeen2026-08-04T00:00:00.000ZJohnson & Johnson filed Form 8-Khttps://www.pharmaradar360.com/article/biontech-filed-form-6-k-f17145941c5b4b05Pharma Surgeen2026-08-04T00:00:00.000ZBioNTech filed Form 6-Khttps://www.pharmaradar360.com/article/otsuka-unveils-unprecedented-phase-3-visionary-two-year-egfr-results-demonstrati-a2e5a108bb07ba54Pharma Surgeen2026-08-04T00:00:00.000ZOtsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathyhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-dcc1639380a83d51Pharma Surgeen2026-08-04T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-57197b1cdd67fc74Pharma Surgeen2026-08-04T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-b81846d6abaf0f3fPharma Surgeen2026-08-04T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-5639069ac7e9bc6aPharma Surgeen2026-08-04T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-066381ac7161a7a0Pharma Surgeen2026-08-04T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-3fb0638a56ceb4d9Pharma Surgeen2026-08-04T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-4243733f02228f9ePharma Surgeen2026-08-04T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-f93675dc33d79be9Pharma Surgeen2026-08-04T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-c417e420cf855c6bPharma Surgeen2026-08-04T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-95654be52e1b7086Pharma Surgeen2026-08-04T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-08a4cdab3be0ecd3Pharma Surgeen2026-08-04T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-19a7b6e3a400f9fdPharma Surgeen2026-08-04T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-2d193e276801d42fPharma Surgeen2026-08-04T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-e0f355ba0886fd05Pharma Surgeen2026-08-04T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-h-e59625a3eca704ebPharma Surgeen2026-08-04T00:00:00.000ZMedicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates; Requirements for Quality Programs; Other Policy Changes; and Adoption of Updated Versions ofhttps://www.pharmaradar360.com/article/national-library-of-medicine-notice-of-partially-closed-meeting-8c99bb36cb1b47afPharma Surgeen2026-08-04T00:00:00.000ZNational Library of Medicine; Notice of Partially Closed Meetinghttps://www.pharmaradar360.com/article/healthcare-advisory-committee-hac-announcement-of-the-hac-meetings-for-fiscal-ye-90da5c81804a7822Pharma Surgeen2026-08-04T00:00:00.000ZHealthcare Advisory Committee (HAC); Announcement of the HAC Meetings for Fiscal Year 2026-2027https://www.pharmaradar360.com/article/cleveland-clinic-one-of-the-nation-s-best-hospitals-9a3467ebc58b15bePharma Surgeen2026-08-04T00:00:00.000ZCleveland Clinic One of the Nation’s Best Hospitalshttps://www.pharmaradar360.com/article/is-krystal-biotech-krys-overvalued-after-q2-earnings-beat-eps-of-1-85-revenue-of-9ac9597e4f904258Pharma Surgeen2026-08-04T00:00:00.000ZIs Krystal Biotech (KRYS) Overvalued After Q2 Earnings Beat? EPS of $1.85 & Revenue of $119.2M; GF Score: 54/100https://www.pharmaradar360.com/article/non-surgical-endodontic-management-of-severe-external-inflammatory-root-resorpti-f2ff558250c82fdbPharma Surgeen2026-08-04T00:00:00.000ZNon-Surgical Endodontic Management of Severe External Inflammatory Root Resorption in a Maxillary First Molar: A Case Report with 12-Month Follow-uphttps://www.pharmaradar360.com/article/high-myopia-associated-strabismus-pathogenesis-clinical-spectrum-and-surgical-ma-0e2bf273883f545fPharma Surgeen2026-08-04T00:00:00.000ZHigh Myopia-Associated Strabismus: Pathogenesis, Clinical Spectrum, and Surgical Managementhttps://www.pharmaradar360.com/article/a-comprehensive-study-on-the-development-of-stimuli-responsive-smart-polymer-sys-7a42d8b2eb1a422cPharma Surgeen2026-08-04T00:00:00.000ZA Comprehensive Study on the Development of Stimuli-Responsive Smart Polymer Systems for Controlled Drug Deliveryhttps://www.pharmaradar360.com/article/transforming-clinical-apheresis-waste-into-a-renewable-source-of-patient-derived-81e8812f544de7b5Pharma Surgeen2026-08-04T00:00:00.000ZTransforming clinical apheresis waste into a renewable source of patient-derived CD34+ hematopoietic stem cell biobank for beta-hemoglobinopathy research and therapeutic discoveryhttps://www.pharmaradar360.com/article/metal-complexes-of-coumarin-derivatives-an-extensive-review-4357c5a6fbdebf1fPharma Surgeen2026-08-04T00:00:00.000ZMetal Complexes of Coumarin derivatives-An Extensive Reviewhttps://www.pharmaradar360.com/article/critical-limits-and-clinical-recommendations-for-notification-of-life-threatenin-2e95ccf220abcaf4Pharma Surgeen2026-08-04T00:00:00.000ZCritical Limits and Clinical Recommendations for Notification of Life-Threatening Glucose Test Results in the 21st Centuryhttps://www.pharmaradar360.com/article/peer-review-report-for-evaluation-and-clinical-relevance-of-plan-quality-indices-b17f2a26a7073755Pharma Surgeen2026-08-04T00:00:00.000ZPeer Review Report For: Evaluation and clinical relevance of plan quality indices in intracavitary brachytherapy for cervical cancer [version 1; peer review: 2 approved]https://www.pharmaradar360.com/article/beyond-diagnosis-why-clinical-curiosity-still-matters-in-psychiatry-4aa0fd8928983525Pharma Surgeen2026-08-04T00:00:00.000ZBeyond Diagnosis: Why Clinical Curiosity Still Matters in Psychiatryhttps://www.pharmaradar360.com/article/the-mediating-role-of-hope-in-the-association-between-resilience-and-psychologic-341eae7e8f9aa774Pharma Surgeen2026-08-04T00:00:00.000ZTHE MEDIATING ROLE OF HOPE IN THE ASSOCIATION BETWEEN RESILIENCE AND PSYCHOLOGICAL DISTRESS AMONG CLINICAL CLERKSHIP STUDENTShttps://www.pharmaradar360.com/article/functional-performance-and-patient-reported-goal-attainment-with-a-novel-micropr-d5e0fa5c9449f4caPharma Surgeen2026-08-04T00:00:00.000ZFunctional Performance and Patient-Reported Goal Attainment with a Novel Microprocessor-Controlled Knee in Active Transfemoral Amputees: A Multicenter Randomized Crossover Trialhttps://www.pharmaradar360.com/article/combined-effects-of-physiotherapy-and-vitamin-d-supplementation-on-pain-disabili-06e737af13eb59cdPharma Surgeen2026-08-04T00:00:00.000ZCombined Effects of Physiotherapy and Vitamin D Supplementation on Pain, Disability, and IL-6 Expression in Chronic Low Back Pain: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/development-of-an-intelligent-clinical-decision-support-system-for-predicting-on-ce55af3215b45515Pharma Surgeen2026-08-04T00:00:00.000ZDevelopment of an Intelligent Clinical Decision Support System for Predicting One-Year CPAP Adherence in Patients with Obstructive Sleep Apnea: A Pilot Studyhttps://www.pharmaradar360.com/article/the-evolution-of-proximal-femur-hemiepiphysiodesis-in-children-with-cerebral-pal-34a8cb830224725cPharma Surgeen2026-08-04T00:00:00.000ZThe Evolution of Proximal Femur Hemiepiphysiodesis in Children with Cerebral Palsyhttps://www.pharmaradar360.com/article/metabolic-indices-of-atherogenicity-insulin-resistance-and-inflammation-aip-tyg-d0c2b0908354c215Pharma Surgeen2026-08-04T00:00:00.000ZMetabolic Indices of Atherogenicity, Insulin Resistance, and Inflammation (AIP, TyG, and CTI) and the Risk of Renal Function Decline in Early-Stage CKM Syndrome: A Nationwide Prospective Cohort Studyhttps://www.pharmaradar360.com/article/the-stiim-up-protocol-exploratory-evaluation-of-the-potential-of-combined-calciu-8c4ca6df13d6be31Pharma Surgeen2026-08-04T00:00:00.000ZThe STIIM UP Protocol: Exploratory Evaluation of the Potential of Combined Calcium Hydroxyapatite, Hyaluronic Acid, and Botulinum Toxin A in Neck Rejuvenationhttps://www.pharmaradar360.com/article/eeg-connectivity-signatures-in-migraine-and-tension-type-headache-a-multimethod-7772e9e6f44a5f16Pharma Surgeen2026-08-04T00:00:00.000ZEEG Connectivity Signatures in Migraine and Tension-Type Headache: A Multimethod ROI-Based Functional Connectivity and Machine-Learning Analysishttps://www.pharmaradar360.com/article/clinical-and-lat1-biomarker-correlates-of-clinical-benefit-from-nanvuranlat-jph2-ba849d7fe34af933Pharma Surgeen2026-08-04T00:00:00.000ZClinical and LAT1 Biomarker Correlates of Clinical Benefit from Nanvuranlat (JPH203) in Advanced Biliary Tract Cancer: A Post Hoc Analysishttps://www.pharmaradar360.com/article/druglm-a-unified-framework-to-enhance-drug-target-interaction-prediction-by-inco-d11b3d7a39fd1889Pharma Surgeen2026-08-04T00:00:00.000ZDrugLM: A Unified Framework to Enhance Drug–Target Interaction Prediction by Incorporating Textual Embeddings via Language Modelshttps://www.pharmaradar360.com/article/immersive-virtual-reality-as-an-auxiliary-intervention-for-college-students-with-511c46aed282a65aPharma Surgeen2026-08-04T00:00:00.000ZImmersive virtual reality as an auxiliary intervention for college students with mild-to-moderate depressive symptoms: a pilot randomized controlled trialhttps://www.pharmaradar360.com/article/spinal-intradural-hematoma-after-intrathecal-drug-delivery-system-implantation-i-c5d99583bd20c3c2Pharma Surgeen2026-08-04T00:00:00.000ZSpinal intradural hematoma after intrathecal drug delivery system implantation in a patient with possible heparin-induced thrombocytopenia: a case reporthttps://www.pharmaradar360.com/article/case-report-pembrolizumab-associated-seronegative-sicca-syndrome-during-continue-2136515cc1f6556dPharma Surgeen2026-08-04T00:00:00.000ZCase Report: Pembrolizumab-associated seronegative sicca syndrome during continued immunotherapy and after drug withdrawal in metastatic urothelial carcinomahttps://www.pharmaradar360.com/article/efficacy-and-safety-of-pain-management-in-perioperative-period-of-tace-in-patien-5e5458938fa13600Pharma Surgeen2026-08-04T00:00:00.000ZEfficacy and safety of pain management in perioperative period of TACE in patients with HCC: a single-center, parallel-group, randomized trialhttps://www.pharmaradar360.com/article/therapeutic-drug-monitoring-with-non-anti-tnf-advanced-therapies-in-inflammatory-f81394b555486ebfPharma Surgeen2026-08-04T00:00:00.000ZTherapeutic drug monitoring with non-anti-TNF advanced therapies in inflammatory bowel disease: current and evolving paradigmshttps://www.pharmaradar360.com/article/fabry-nephropathy-as-the-clinical-anchor-for-kidney-centered-metabolic-surveilla-1ba2ad08f33433dfPharma Surgeen2026-08-04T00:00:00.000ZFabry nephropathy as the clinical anchor for kidney-centered metabolic surveillance: linking genetic heterogeneity to early risk identificationhttps://www.pharmaradar360.com/article/autoimmune-hypothyroidism-and-endometriosis-evidence-from-bidirectional-mendelia-aec4bc2c7394cc7aPharma Surgeen2026-08-04T00:00:00.000ZAutoimmune hypothyroidism and endometriosis: evidence from bidirectional Mendelian randomization and an independent clinical cohort analysishttps://www.pharmaradar360.com/article/association-between-a-clinical-pharmacist-led-multimodal-remote-medication-inter-24f025931802ad4bPharma Surgeen2026-08-04T00:00:00.000ZAssociation between a clinical pharmacist–led multimodal remote medication intervention and individualized treatment outcomes in patients with type 2 diabetes mellitushttps://www.pharmaradar360.com/article/is-age-still-a-barrier-in-ventricular-tachycardia-ablation-a-study-of-safety-eff-72dd5fb9d14d8c10Pharma Surgeen2026-08-04T00:00:00.000ZIs age still a barrier in ventricular tachycardia ablation? A study of safety, efficacy and clinical outcomes in the elderlyhttps://www.pharmaradar360.com/article/in-vitro-and-molecular-docking-evaluation-of-apigenin-7-o-glucuronide-from-psoro-bcab7cdeca5d0bc8Pharma Surgeen2026-08-04T00:00:00.000ZIn vitro and molecular docking evaluation of apigenin-7-O-glucuronide from Psorospermum febrifugum as anti-inflammatory and predicted antiplasmodial compoundhttps://www.pharmaradar360.com/article/protocol-for-a-small-scale-mixed-methods-efficacy-trial-of-a-novel-co-designed-d-b0b246f836281506Pharma Surgeen2026-08-04T00:00:00.000ZProtocol for a small-scale mixed methods efficacy trial of a novel co-designed digital health intervention targeting emotion dysregulation in adolescents with ADHD symptomshttps://www.pharmaradar360.com/article/design-synthesis-amp-biological-evaluation-of-oxazole-derivatives-for-antimicrob-325df14dd821d80cPharma Surgeen2026-08-04T00:00:00.000ZDESIGN, SYNTHESIS &amp; BIOLOGICAL EVALUATION OF OXAZOLE DERIVATIVES FOR ANTIMICROBIAL ACTIVITYhttps://www.pharmaradar360.com/article/hptlc-fingerprint-profiling-and-phytochemical-characterization-of-haridradi-chur-ca11724b4011778dPharma Surgeen2026-08-04T00:00:00.000ZHPTLC Fingerprint Profiling and Phytochemical Characterization of Haridradi Churnahttps://www.pharmaradar360.com/article/a-correlation-study-parental-bonding-self-esteem-and-academic-motivation-among-a-5ce53713862cb80aPharma Surgeen2026-08-04T00:00:00.000ZA correlation study: Parental Bonding, Self-Esteem and Academic Motivation among adolescentshttps://www.pharmaradar360.com/article/beyond-leave-nothing-behind-reconsidering-biological-restoration-after-drug-coat-fad535d92e2e4c59Pharma Surgeen2026-08-04T00:00:00.000ZBeyond �leave nothing behind�: reconsidering biological restoration after drug-coated balloon coronary intervention. Responsehttps://www.pharmaradar360.com/article/thanatophoric-dysplasia-prevalence-clinical-characteristics-and-molecular-findin-74f0f42c9082561bPharma Surgeen2026-08-04T00:00:00.000ZThanatophoric dysplasia: prevalence, clinical characteristics, and molecular findings in a public hospital from Western Mexicohttps://www.pharmaradar360.com/article/clinical-and-molecular-characterization-of-six-mexican-patients-with-fgfr2-relat-8fa0c2156b950935Pharma Surgeen2026-08-04T00:00:00.000ZClinical and molecular characterization of six Mexican patients with FGFR2-related syndromic craniosynostosishttps://www.pharmaradar360.com/article/desafios-asistenciales-en-el-manejo-del-adenocarcinoma-de-pulmon-en-estadio-iii-02a3d42b53d184a7Pharma Surgeen2026-08-04T00:00:00.000ZDesafíos asistenciales en el manejo del adenocarcinoma de pulmón en estadio III con mutación de EGFR: integración de la cirugía y la terapia adyuvante en la era post-ADAURAhttps://www.pharmaradar360.com/article/mas-alla-del-0-respuesta-mantenida-a-quimioinmunoterapia-en-pd-l1-negativo-e3750f0f79fafb42Pharma Surgeen2026-08-04T00:00:00.000ZMás allá del 0%: respuesta mantenida a quimioinmunoterapia en PD-L1 negativohttps://www.pharmaradar360.com/article/largo-superviviente-en-carcinoma-microcitico-de-pulmon-avanzado-papel-de-la-inmu-3c8a236edbd4800bPharma Surgeen2026-08-04T00:00:00.000ZLargo superviviente en carcinoma microcítico de pulmón avanzado: papel de la inmunoterapia de mantenimiento y tratamiento local de la oligoprogresiónhttps://www.pharmaradar360.com/article/prognostic-stratification-in-a-diabetic-kidney-disease-trial-using-plasma-concen-5e3a15921fe545f0Pharma Surgeen2026-08-04T00:00:00.000ZPrognostic stratification in a diabetic kidney disease trial using plasma concentrations of soluble tumor necrosis factor receptor 1https://www.pharmaradar360.com/article/the-intravenous-formulation-exposome-in-critical-illness-a-clinical-pharmacology-3c8c7e0dacfc85bfPharma Surgeen2026-08-04T00:00:00.000ZThe intravenous formulation exposome in critical illness: a clinical pharmacology framework for fluid, electrolyte, energy and excipient exposurehttps://www.pharmaradar360.com/article/a-cross-sectional-pharmacovigilance-study-of-adverse-drug-reactions-in-patients-fc75327c120aa1d0Pharma Surgeen2026-08-04T00:00:00.000ZA Cross-Sectional Pharmacovigilance Study of Adverse Drug Reactions in Patients with Mental Health Disorders at the Social Rehabilitation Yogyakartahttps://www.pharmaradar360.com/article/comparison-of-remimazolam-total-intravenous-anesthesia-versus-sevoflurane-inhala-707db3152e5cdc1bPharma Surgeen2026-08-04T00:00:00.000ZComparison of remimazolam total intravenous anesthesia versus sevoflurane inhalational anesthesia on emergence agitation in patients undergoing laparoscopic surgery for gastric or colorectal cancer: study protocol for a randomized controlled trialhttps://www.pharmaradar360.com/article/religion-spirituality-addiction-guilt-and-shame-a-systematic-review-of-mechanism-44ca3ef6a51ac5cePharma Surgeen2026-08-04T00:00:00.000ZReligion, Spirituality, Addiction, Guilt, and Shame: A Systematic Review of Mechanisms, Outcomes, and Clinical Implicationshttps://www.pharmaradar360.com/article/right-ventricular-dysfunction-in-acute-pulmonary-embolism-clinical-characteristi-8728c7af04e11fe8Pharma Surgeen2026-08-04T00:00:00.000ZRight Ventricular Dysfunction in Acute Pulmonary Embolism: Clinical Characteristics and Predictors of In-Hospital Mortality at a Tertiary Hospital in Mogadishu, Somaliahttps://www.pharmaradar360.com/article/new-drug-elafibranor-for-primary-biliary-cholangitis-9463213deca3dd49Pharma Surgeen2026-08-04T00:00:00.000ZNew Drug: Elafibranor for primary biliary cholangitishttps://www.pharmaradar360.com/article/changes-in-the-biophysical-parameters-of-the-skin-barrier-in-pressure-prone-area-078d4fc7e44bb0c6Pharma Surgeen2026-08-04T00:00:00.000ZChanges in the Biophysical Parameters of the Skin Barrier in Pressure-Prone Areas in Patients with Limited Mobility During Early Post-Stroke Rehabilitation: Clinical Case Reportshttps://www.pharmaradar360.com/article/structural-characterization-of-new-8-17-epoxybriarane-diterpenoids-from-the-octo-0f071b6b35aa03bdPharma Surgeen2026-08-04T00:00:00.000ZStructural Characterization of New 8,17-Epoxybriarane Diterpenoids from the Octocoral &lt;i&gt;Briareum stechei&lt;/i&gt;https://www.pharmaradar360.com/article/the-effect-of-fenugreek-oral-capsule-on-the-sleep-quality-of-primiparous-women-i-8dcc3545e5b761bePharma Surgeen2026-08-04T00:00:00.000ZThe effect of fenugreek oral capsule on the sleep quality of primiparous women in the postpartum period: a triple‑blind randomized controlled trialhttps://www.pharmaradar360.com/article/correlation-between-high-risk-human-papillomavirus-hpv-viral-load-and-cervical-l-f119909e1bcfc2a8Pharma Surgeen2026-08-04T00:00:00.000ZCorrelation between high-risk Human Papillomavirus (HPV) viral load and cervical lesions across different subtypes, along with the development of a clinical prediction modelhttps://www.pharmaradar360.com/article/effect-of-a-free-sugar-restricted-diet-on-anthropometric-parameters-lipid-profil-511f93d69dc5ae05Pharma Surgeen2026-08-04T00:00:00.000ZEffect of a free sugar-restricted diet on anthropometric parameters, lipid profile, and glycemic control in women with polycystic ovary syndrome: a randomized controlled trialhttps://www.pharmaradar360.com/article/effect-of-postpartum-probiotic-supplementation-on-breastmilk-composition-and-inf-c2dc26c7b92eebe2Pharma Surgeen2026-08-04T00:00:00.000ZEffect of postpartum probiotic supplementation on breastmilk composition and infant health: a pilot randomized controlled trialhttps://www.pharmaradar360.com/article/effects-of-dairy-product-intake-and-home-based-resistance-exercise-on-the-physic-6ddcb68916d98512Pharma Surgeen2026-08-04T00:00:00.000ZEffects of dairy product intake and home-based resistance exercise on the physical function in Japanese community-dwelling older adults: results of a real-world randomized controlled trialhttps://www.pharmaradar360.com/article/selected-clinical-parameters-of-cardiology-patients-their-health-promoting-behav-b9a22c0a1d1adebbPharma Surgeen2026-08-04T00:00:00.000ZSelected clinical parameters of cardiology patients, their health-promoting behaviors and quality of life in relation to body mass indexhttps://www.pharmaradar360.com/article/adaptive-versus-fixed-designs-in-confirmatory-clinical-trials-centering-the-choi-8c61aab83a72bc7bPharma Surgeen2026-08-04T00:00:00.000ZAdaptive versus fixed designs in confirmatory clinical trials: centering the choice on ethicshttps://www.pharmaradar360.com/article/the-effect-of-mindfulness-based-psychoeducation-program-on-mindfulness-self-comp-8324d5fdddd17e1cPharma Surgeen2026-08-04T00:00:00.000ZThe Effect of Mindfulness-Based Psychoeducation Program on Mindfulness, Self-Compassion, and Forgiveness Tendencies of Patients with Bipolar Disorder: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/synergism-in-drug-combination-of-new-tuberculosis-antibiotics-for-drug-resistant-0dda8a81509e3238Pharma Surgeen2026-08-04T00:00:00.000ZSynergism in drug combination of new tuberculosis antibiotics for drug-resistant <i>Mycobacterium tuberculosis in vitro</i>https://www.pharmaradar360.com/article/types-i-ii-v-and-vi-secretion-system-genes-in-clinical-uropathogenic-i-escherich-6d51714c67aeb5c1Pharma Surgeen2026-08-04T00:00:00.000ZTypes I, II, V, and VI secretion system genes in clinical uropathogenic <i>Escherichia coli</i> associate with antibiotic susceptibility, biofilm formation, and persister cellshttps://www.pharmaradar360.com/article/advancement-of-lamp-technologies-for-rapid-and-accurate-diagnosis-of-infectious-d73808018205afa5Pharma Surgeen2026-08-04T00:00:00.000ZAdvancement of LAMP technologies for rapid and accurate diagnosis of infectious diseaseshttps://www.pharmaradar360.com/article/the-effect-of-orthodontic-tooth-movement-on-intrabony-periodontal-defects-after-3a7653689fcd08f8Pharma Surgeen2026-08-04T00:00:00.000ZThe Effect of Orthodontic Tooth Movement on Intrabony Periodontal Defects After Guided Tissue Regeneration. Part <scp>II</scp> : The Evaluation of Clinical and Radiological Parameters in a Randomised Controlled Clinical Trialhttps://www.pharmaradar360.com/article/nucleos-t-ide-withdrawal-vs-nucleos-t-ide-withdrawal-with-adjuvant-pegylated-int-853bfa0316142304Pharma Surgeen2026-08-04T00:00:00.000ZNucleos(t)ide withdrawal vs Nucleos(t)ide withdrawal with adjuvant pegylated-interferon in HBeAg-negative hepatitis B virus infection (NUC-B Trial)https://www.pharmaradar360.com/article/letter-to-the-editor-a-novel-classification-system-for-fifth-metatarsal-base-fra-e81ed260bf861a88Pharma Surgeen2026-08-04T00:00:00.000ZLetter to the Editor: A Novel Classification System for Fifth Metatarsal Base Fractures Is Reliable and Clinically Validatedhttps://www.pharmaradar360.com/article/clinical-decision-support-to-reduce-opioid-prescribing-at-discharge-for-inpatien-7b644f2593912463Pharma Surgeen2026-08-04T00:00:00.000ZClinical Decision Support to Reduce Opioid Prescribing at Discharge for Inpatients Undergoing Surgery (LESS Study): An Interrupted Time Series Analysishttps://www.pharmaradar360.com/article/cerebral-aspergillosis-under-ibrutinib-therapy-clinical-features-and-management-cef0c4618822546bPharma Surgeen2026-08-04T00:00:00.000ZCerebral aspergillosis under ibrutinib therapy: clinical features and management challengeshttps://www.pharmaradar360.com/article/transitioning-ai-based-sperm-assessment-from-proof-of-concept-to-clinical-practi-3b05cf432c68046aPharma Surgeen2026-08-04T00:00:00.000ZTransitioning AI-based sperm assessment from proof-of-concept to clinical practicehttps://www.pharmaradar360.com/article/latent-profiles-of-social-isolation-and-loneliness-and-their-associations-with-i-3c8fe81adc4acb57Pharma Surgeen2026-08-04T00:00:00.000ZLatent profiles of social isolation and loneliness and their associations with inflammation and clinical outcomes in older patients with heart failure: A prospective longitudinal studyhttps://www.pharmaradar360.com/article/fear-of-clofazimine-induced-skin-discoloration-as-a-barrier-to-leprosy-treatment-59a09b4ac70cc863Pharma Surgeen2026-08-04T00:00:00.000ZFear of clofazimine-induced skin discoloration as a barrier to leprosy treatment: urgent need for alternative therapeutic optionshttps://www.pharmaradar360.com/article/the-social-insensitivity-of-clinical-delusions-c668a23c154aad34Pharma Surgeen2026-08-04T00:00:00.000ZThe Social Insensitivity of Clinical Delusionshttps://www.pharmaradar360.com/article/the-social-determinants-and-focus-of-clinical-delusions-872c20d60a1b5eb3Pharma Surgeen2026-08-04T00:00:00.000ZThe Social Determinants and Focus of Clinical Delusionshttps://www.pharmaradar360.com/article/individualistic-accounts-of-clinical-delusions-417b1b5d3ec7d104Pharma Surgeen2026-08-04T00:00:00.000ZIndividualistic Accounts of Clinical Delusionshttps://www.pharmaradar360.com/article/clinical-and-genetic-risk-factors-for-anthracycline-induced-cardiotoxicity-in-ch-039e95f466e56ee9Pharma Surgeen2026-08-04T00:00:00.000ZClinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene studyhttps://www.pharmaradar360.com/article/ubiquitin-family-as-novel-protein-partners-for-molecular-glues-fa5d203a1dc0501aPharma Surgeen2026-08-04T00:00:00.000ZUbiquitin family as novel protein partners for molecular glueshttps://www.pharmaradar360.com/article/uterine-artery-bulldog-clamping-versus-tourniquet-for-reducing-blood-loss-in-ope-9d9d6d02ba015954Pharma Surgeen2026-08-04T00:00:00.000ZUterine artery bulldog clamping versus tourniquet for reducing blood loss in open myomectomy: a randomized controlled trialhttps://www.pharmaradar360.com/article/the-microbiological-spectrum-and-clinical-course-of-adolescents-and-adults-with-be1aa96ebd7f1f1fPharma Surgeen2026-08-04T00:00:00.000ZThe microbiological spectrum and clinical course of adolescents and adults with peritonsillar abscesseshttps://www.pharmaradar360.com/article/the-landscape-and-plasticity-of-transposable-element-expression-in-an-adult-stem-5045c61839f4f103Pharma Surgeen2026-08-04T00:00:00.000ZThe landscape and plasticity of transposable element expression in an adult stem cell of high physiological and clinical significancehttps://www.pharmaradar360.com/article/global-trends-in-artificial-intelligence-applications-in-medical-imaging-and-imp-dcbd060082882ab4Pharma Surgeen2026-08-04T00:00:00.000ZGlobal trends in artificial intelligence applications in medical imaging and implications for clinical practicehttps://www.pharmaradar360.com/article/hepatic-sarcoidosis-presenting-with-portal-hypertension-without-histologically-e-d31f44434d6ee2a3Pharma Surgeen2026-08-04T00:00:00.000ZHepatic sarcoidosis presenting with portal hypertension without histologically established cirrhosis and reticular hepatic imaging featureshttps://www.pharmaradar360.com/article/identification-of-novel-diagnostic-markers-in-progressive-bone-mineral-density-l-cbe1a5b4eae73aafPharma Surgeen2026-08-04T00:00:00.000ZIdentification of novel diagnostic markers in progressive bone mineral density loss via serum proteomics analysis using orbitrap mass spectrometryhttps://www.pharmaradar360.com/article/oxidative-stress-and-il-36-mediated-inflammation-in-osteoarthritis-association-w-d8a16150a407c636Pharma Surgeen2026-08-04T00:00:00.000ZOxidative Stress and IL-36α–Mediated Inflammation in Osteoarthritis: Association with Tryptophan–Kynurenine Metabolismhttps://www.pharmaradar360.com/article/rapid-antimicrobial-susceptibility-testing-bridging-commercial-platforms-and-eme-bc1fce77b56de9c1Pharma Surgeen2026-08-04T00:00:00.000ZRapid antimicrobial susceptibility testing: bridging commercial platforms and emerging technologies toward clinical implementationhttps://www.pharmaradar360.com/article/comparative-analysis-of-supervised-machine-learning-algorithms-for-transdermal-d-524da7d5b3afbe27Pharma Surgeen2026-08-04T00:00:00.000ZComparative analysis of supervised machine learning algorithms for transdermal drug delivery in brain disordershttps://www.pharmaradar360.com/article/reducing-time-to-result-in-bloodstream-infections-comparative-evaluation-of-vite-374dc78918fdc044Pharma Surgeen2026-08-04T00:00:00.000ZReducing time-to-result in bloodstream infections: comparative evaluation of VITEK® REVEAL™ and QuickMIC® for rapid phenotypic antimicrobial susceptibility testinghttps://www.pharmaradar360.com/article/association-of-urinary-albumin-to-creatinine-ratio-with-all-cause-and-cardiovasc-c9d04bba7551b0a3Pharma Surgeen2026-08-04T00:00:00.000ZAssociation of urinary albumin-to-creatinine ratio with all-cause and cardiovascular disease mortality risk in patients with osteoarthritis: a prospective cohort studyhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-add-on-topiramate-vs-metformin-on-cardiometabolic-profile-6af83a815dee7ac4Pharma Surgeen2026-08-04T00:00:00.000ZEfficacy and safety of add-on topiramate vs. metformin on cardiometabolic profile in patients of schizophrenia on atypical antipsychotics with metabolic syndrome: an active-controlled, rater-blinded, parallel-design randomized controlled trialhttps://www.pharmaradar360.com/article/investigating-changes-in-the-blood-brain-barrier-in-schizophrenia-spectrum-disor-95bde52333918142Pharma Surgeen2026-08-04T00:00:00.000ZInvestigating changes in the blood-brain barrier in schizophrenia spectrum disorders: design and methodology of a longitudinal dynamic contrast-enhanced MRI studyhttps://www.pharmaradar360.com/article/a-mortality-model-for-relapsed-or-refractory-multiple-myeloma-emulation-of-subje-d90612a075563aa2Pharma Surgeen2026-08-04T00:00:00.000ZA mortality model for relapsed or refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world datahttps://www.pharmaradar360.com/article/subtractive-proteomics-assisted-putative-drug-target-and-inhibitor-identificatio-21638f0b2cdff550Pharma Surgeen2026-08-04T00:00:00.000ZSubtractive proteomics-assisted putative drug target and inhibitor identification: a study based on six Candida specieshttps://www.pharmaradar360.com/article/hhv-8-infection-in-solid-organ-transplant-pathogenesis-epidemiology-clinical-man-7fef90a0adfff0a8Pharma Surgeen2026-08-04T00:00:00.000ZHHV‐8 Infection in Solid‐Organ Transplant—Pathogenesis, Epidemiology, Clinical Manifestations and Managementhttps://www.pharmaradar360.com/article/what-drives-prolonged-hospital-stays-in-schizophrenia-spectrum-disorders-a-canad-65d7c960a5946d0ePharma Surgeen2026-08-04T00:00:00.000ZWhat drives prolonged hospital stays in schizophrenia‐spectrum disorders? A Canadian tertiary care reviewhttps://www.pharmaradar360.com/article/tongue-grooving-during-drug-induced-sleep-endoscopy-a-novel-tool-to-evaluate-the-34c6260008caa17aPharma Surgeen2026-08-04T00:00:00.000ZTongue Grooving During Drug‐Induced Sleep Endoscopy: A Novel Tool to Evaluate the Airwayhttps://www.pharmaradar360.com/article/consensus-recommendations-for-technical-standardization-of-flow-cytometric-measu-c92fc1e93369c47ePharma Surgeen2026-08-04T00:00:00.000ZConsensus recommendations for technical standardization of flow cytometric measurable residual disease assessment in <scp>B</scp> ‐cell acute lymphoblastic leukemia: A report from <scp>The Cytometry Society, India</scp>https://www.pharmaradar360.com/article/drug-repurposing-in-sickle-cell-disease-evaluating-imatinib-as-a-therapeutic-can-98ba364d5306e280Pharma Surgeen2026-08-04T00:00:00.000ZDrug Repurposing in Sickle Cell Disease: Evaluating Imatinib as a Therapeutic Candidatehttps://www.pharmaradar360.com/article/nct07746141-a-first-in-human-study-investigating-bg-85738-alone-or-in-combinatio-d57acbcdd43f81d1Pharma Surgeen2026-08-04T00:00:00.000ZNCT07746141: A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutationshttps://www.pharmaradar360.com/article/nct07745790-safety-and-efficacy-of-multimodal-thermal-therapy-mtt-combined-with-fb52b9a19540f75aPharma Surgeen2026-08-04T00:00:00.000ZNCT07745790: Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancerhttps://www.pharmaradar360.com/article/nct07745491-pneumonia-after-cardiovascular-surgery-with-an-artificial-intelligen-cc62ba9c654e2273Pharma Surgeen2026-08-04T00:00:00.000ZNCT07745491: Pneumonia After Cardiovascular Surgery With an Artificial Intelligencehttps://www.pharmaradar360.com/article/nct07745322-spatial-msc-index-for-predicting-anti-pd-1-efficacy-in-esophageal-ca-9d96d4e12ce07e85Pharma Surgeen2026-08-04T00:00:00.000ZNCT07745322: Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancerhttps://www.pharmaradar360.com/article/nct07745010-radicle-energytm-dnb-a-study-assessing-the-impact-of-health-and-well-5b8914bf6b65e42dPharma Surgeen2026-08-04T00:00:00.000ZNCT07745010: Radicle Energy™ DNB: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomeshttps://www.pharmaradar360.com/article/nct07744958-restore-bladder-registry-on-strategies-for-organ-preservation-in-mus-bc3b53e8fc890b8cPharma Surgeen2026-08-04T00:00:00.000ZNCT07744958: RESTORE-BLADDER (REgistry on STrategies for Organ pREservation in Muscle-invasive BLADDER Cancer)https://www.pharmaradar360.com/article/nct07744295-preoperative-anxiety-and-depression-among-older-chinese-patients-ef52486ee82d35bfPharma Surgeen2026-08-04T00:00:00.000ZNCT07744295: Preoperative Anxiety and Depression Among Older Chinese Patientshttps://www.pharmaradar360.com/article/nct07743580-a-study-of-secutrelvir-in-participants-with-coronavirus-disease-2019-4259a4e44c26e609Pharma Surgeen2026-08-04T00:00:00.000ZNCT07743580: A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Diseasehttps://www.pharmaradar360.com/article/nct07743541-study-of-tub-040-in-patients-with-recurrent-or-progressive-uterine-c-8ba682345bc040d8Pharma Surgeen2026-08-04T00:00:00.000ZNCT07743541: Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapyhttps://www.pharmaradar360.com/article/nct07743528-a-prospective-multicenter-two-cohorts-single-arm-study-evaluating-sa-ceaf014300e558e4Pharma Surgeen2026-08-04T00:00:00.000ZNCT07743528: A Prospective, Multicenter, Two-cohorts, Single Arm Study Evaluating Safety, Effectiveness and Performance of Angimis Atherectomy System for the Treatment of Non-crossable and/or Non-dilatablE Lesions in CorONary Arteries Disease (NEON Study).https://www.pharmaradar360.com/article/nct07728890-effect-of-box-breathing-exercise-on-anxiety-pain-and-pulmonary-funct-c8d0ad2a7d947b9cPharma Surgeen2026-08-04T00:00:00.000ZNCT07728890: Effect of Box Breathing Exercise on Anxiety, Pain, and Pulmonary Function Tests in Patients Undergoing Colonoscopyhttps://www.pharmaradar360.com/article/nct07724197-pulsatile-electrical-impedance-tomography-for-diagnosis-and-monitori-e210f80563f743ecPharma Surgeen2026-08-04T00:00:00.000ZNCT07724197: Pulsatile Electrical Impedance Tomography for Diagnosis and Monitoring of Acute Pulmonary Embolismhttps://www.pharmaradar360.com/article/nct07672483-il-12-genetically-engineered-myeloid-cells-in-participants-with-rela-86a1e9a7db237897Pharma Surgeen2026-08-04T00:00:00.000ZNCT07672483: IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumorshttps://www.pharmaradar360.com/article/nct07642765-easix-score-and-post-induction-hypotension-in-frail-patients-undergo-81fc5904a8a66669Pharma Surgeen2026-08-04T00:00:00.000ZNCT07642765: EASIX Score and Post-Induction Hypotension in Frail Patients Undergoing Non-Cardiac Surgeryhttps://www.pharmaradar360.com/article/nct07587242-a-phase-3-study-to-evaluate-the-safety-and-efficacy-of-aoc-1044-also-57c96ab7edf25697Pharma Surgeen2026-08-04T00:00:00.000ZNCT07587242: A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skippinghttps://www.pharmaradar360.com/article/nct07539311-study-to-assess-the-efficacy-and-safety-of-rina-s-in-participants-wi-17280bfeb0b28b57Pharma Surgeen2026-08-04T00:00:00.000ZNCT07539311: Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancershttps://www.pharmaradar360.com/article/nct07409194-the-effect-of-acupressure-on-hyperbilirubinemia-in-newborns-a-random-4eaf3e1521a689e3Pharma Surgeen2026-08-04T00:00:00.000ZNCT07409194: The Effect of Acupressure on Hyperbilirubinemia in Newborns: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07408089-study-of-the-kinesin-oral-molecular-degrader-bbi-940-in-subjects-wit-d5508f3f7bd9315bPharma Surgeen2026-08-04T00:00:00.000ZNCT07408089: Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancerhttps://www.pharmaradar360.com/article/nct07388550-phase-i-open-label-safety-trial-of-pembrolizumab-for-neurological-po-c8883fe8549f9913Pharma Surgeen2026-08-04T00:00:00.000ZNCT07388550: Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)https://www.pharmaradar360.com/article/nct07306559-a-study-to-test-how-well-different-doses-of-bi-3820768-are-tolerated-7545e0d9c64c96f4Pharma Surgeen2026-08-04T00:00:00.000ZNCT07306559: A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)https://www.pharmaradar360.com/article/nct07226206-a-gene-therapy-study-of-spk-8011qq-in-adults-with-severe-or-moderate-86a552e9d05ea1c7Pharma Surgeen2026-08-04T00:00:00.000ZNCT07226206: A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia Ahttps://www.pharmaradar360.com/article/nct07225686-maridebart-cafraglutide-versus-placebo-in-adult-participants-with-ob-7a4bac25506aaab2Pharma Surgeen2026-08-04T00:00:00.000ZNCT07225686: Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapyhttps://www.pharmaradar360.com/article/nct07181447-nirs-for-the-diagnosis-of-myofascial-pelvic-pain-c66295004276a64bPharma Surgeen2026-08-04T00:00:00.000ZNCT07181447: NIRS for the Diagnosis of Myofascial Pelvic Painhttps://www.pharmaradar360.com/article/nct07169630-pet-imaging-of-phosphodiesterase-4-pde4-in-volunteers-with-alzheimer-ad9bf3a66aac9969Pharma Surgeen2026-08-04T00:00:00.000ZNCT07169630: PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)https://www.pharmaradar360.com/article/nct07161830-evaluating-the-efficacy-of-ocmtm-omeza-complete-matrix-in-the-treatm-54c49bc0956e48eePharma Surgeen2026-08-04T00:00:00.000ZNCT07161830: Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcershttps://www.pharmaradar360.com/article/nct07161388-durvalumab-consolidation-after-chemoradiation-therapy-for-limited-st-d642bf4a6b8570dePharma Surgeen2026-08-04T00:00:00.000ZNCT07161388: Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in Chinahttps://www.pharmaradar360.com/article/nct07111559-lacunar-stroke-hyperacute-clinical-utilization-of-novel-approach-reg-2964bdb966a79cb4Pharma Surgeen2026-08-04T00:00:00.000ZNCT07111559: Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trialhttps://www.pharmaradar360.com/article/nct06904066-autologous-t-cells-transduced-with-retroviral-vectors-expressing-tcr-8a1bed717e911091Pharma Surgeen2026-08-04T00:00:00.000ZNCT06904066: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancieshttps://www.pharmaradar360.com/article/nct06876142-combination-therapy-mirdametinib-and-sirolimus-for-ras-mutated-relap-84e0260330113171Pharma Surgeen2026-08-04T00:00:00.000ZNCT06876142: Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/nct06822842-accurate-diagnosis-and-grading-of-pediatric-solid-tumors-based-on-pa-e46132fc9db184bfPharma Surgeen2026-08-04T00:00:00.000ZNCT06822842: Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Modelshttps://www.pharmaradar360.com/article/nct06770582-testing-the-addition-of-the-immunotherapy-drug-pembrolizumab-to-radi-9353a23a973b2a32Pharma Surgeen2026-08-04T00:00:00.000ZNCT06770582: Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trialhttps://www.pharmaradar360.com/article/nct06665100-pul-042-treatment-in-patients-with-parainfluenza-virus-piv-human-met-70a3fdab791c4549Pharma Surgeen2026-08-04T00:00:00.000ZNCT06665100: PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)https://www.pharmaradar360.com/article/nct06619509-a-study-to-test-long-term-treatment-with-brigimadlin-in-people-with-0c36d1dadf8ae1c3Pharma Surgeen2026-08-04T00:00:00.000ZNCT06619509: A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicinehttps://www.pharmaradar360.com/article/nct06595940-genetic-analysis-of-uncommon-disease-presentations-in-non-us-populat-9a7defcdd77feca2Pharma Surgeen2026-08-04T00:00:00.000ZNCT06595940: Genetic Analysis of Uncommon Disease Presentations in Non-US Populationshttps://www.pharmaradar360.com/article/nct06517693-safety-and-pharmacokinetics-study-of-pgt121-414-ls-alone-and-in-comb-330af493c532edecPharma Surgeen2026-08-04T00:00:00.000ZNCT06517693: Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1https://www.pharmaradar360.com/article/nct06434272-blood-flow-restriction-exercise-in-patients-with-an-achilles-tendon-1c0afaae0b3d6a4dPharma Surgeen2026-08-04T00:00:00.000ZNCT06434272: Blood Flow Restriction Exercise in Patients With an Achilles Tendon Rupturehttps://www.pharmaradar360.com/article/nct06411210-obesity-complicating-type-1-diabetes-glp-1-analogue-anti-obesity-tre-c927b77a5613ad40Pharma Surgeen2026-08-04T00:00:00.000ZNCT06411210: Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatmenthttps://www.pharmaradar360.com/article/nct05906537-skb410-for-injection-in-solid-tumors-be4d5b348ea60debPharma Surgeen2026-08-04T00:00:00.000ZNCT05906537: SKB410 for Injection in Solid Tumorshttps://www.pharmaradar360.com/article/nct05889182-a-study-to-assess-change-in-disease-activity-and-adverse-events-of-o-e3b3f7628bae73a3Pharma Surgeen2026-08-04T00:00:00.000ZNCT05889182: A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapyhttps://www.pharmaradar360.com/article/nct05739981-phase-ii-imnn-001-also-known-as-gen-1-on-sll-with-bev-and-nact-newly-3db7099f2a693973Pharma Surgeen2026-08-04T00:00:00.000ZNCT05739981: Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancerhttps://www.pharmaradar360.com/article/nct05713799-trial-of-the-combination-of-alpha-lipoic-acid-and-mirabegron-in-wome-58ca62d5ec6a8459Pharma Surgeen2026-08-04T00:00:00.000ZNCT05713799: Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesityhttps://www.pharmaradar360.com/article/nct05554406-testing-new-therapies-for-patients-with-acute-myeloid-leukemia-who-a-7ba612c389b9cb0ePharma Surgeen2026-08-04T00:00:00.000ZNCT05554406: Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)https://www.pharmaradar360.com/article/nct05050916-the-investigation-of-vitamin-d-and-menstrual-cycles-trial-the-invitd-8f3a6b794c9ea7f4Pharma Surgeen2026-08-04T00:00:00.000ZNCT05050916: The Investigation of Vitamin D and Menstrual Cycles Trial, the inVitD Trial: A Phase II Clinical Trialhttps://www.pharmaradar360.com/article/nct04739800-comparison-of-standard-of-care-treatment-with-a-triplet-combination-b522211641599461Pharma Surgeen2026-08-04T00:00:00.000ZNCT04739800: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agentshttps://www.pharmaradar360.com/article/nct04310007-testing-the-addition-of-the-pill-chemotherapy-cabozantinib-to-the-st-82ffea64c29a1726Pharma Surgeen2026-08-04T00:00:00.000ZNCT04310007: Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancerhttps://www.pharmaradar360.com/article/nct04040634-optimal-blood-pressure-for-the-prevention-of-major-vascular-events-i-63c1f43649659b86Pharma Surgeen2026-08-04T00:00:00.000ZNCT04040634: Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)https://www.pharmaradar360.com/article/nct03474718-evaluating-the-efficacy-of-platelet-rich-plasma-therapy-in-the-treat-6a84131d18b98af6Pharma Surgeen2026-08-04T00:00:00.000ZNCT03474718: Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopeciahttps://www.pharmaradar360.com/article/nct03191149-testing-osimertinib-as-a-treatment-for-lung-cancers-with-an-egfr-exo-32da64fc69106436Pharma Surgeen2026-08-04T00:00:00.000ZNCT03191149: Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Changehttps://www.pharmaradar360.com/article/nct02257528-nivolumab-in-treating-patients-with-persistent-recurrent-or-metastat-3b958a92942f0269Pharma Surgeen2026-08-04T00:00:00.000ZNCT02257528: Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancerhttps://www.pharmaradar360.com/article/nct01747213-bisnorcymserine-in-healthy-adult-volunteers-debed50654ad5b89Pharma Surgeen2026-08-04T00:00:00.000ZNCT01747213: Bisnorcymserine in Healthy Adult Volunteershttps://www.pharmaradar360.com/article/nct01571752-health-outcomes-by-neighborhood-baltimore-77f43340d1effb6fPharma Surgeen2026-08-04T00:00:00.000ZNCT01571752: Health Outcomes by Neighborhood - Baltimorehttps://www.pharmaradar360.com/article/nct01386424-screening-for-lid-clinical-studies-unit-healthy-volunteer-protocols-c2fb2775f0963edePharma Surgeen2026-08-04T00:00:00.000ZNCT01386424: Screening for LID Clinical Studies Unit Healthy Volunteer Protocolshttps://www.pharmaradar360.com/article/nct01352962-gemcitabine-carboplatin-and-lenalidomide-for-treatment-of-advanced-m-95b02a029d39e77dPharma Surgeen2026-08-04T00:00:00.000ZNCT01352962: Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors